Retrophin plots a $40M IPO amid a spree of deals

Damian Garde It's been a busy month for Retrophin, and CEO Martin Shkreli is capping it off with an IPO filing, looking to take his company from over-the-counter trading to the ...

As GSK hails its FDA nod for Anoro, a Novartis Advair knockoff prepares for its close-up

Carly Helfand GlaxoSmithKline's Advair is not your average off-patent blockbuster. It's difficult to copy, which has held off any major generic competition to date. Now, Novartis' ...

Branded or Generic? Adults Share Preferences in Study

mia.burns By Mia Burns (mia.burns@ubm.com) Close to 16 percent, or 37 million of adults agree that paying more for branded prescription medications rather than getting generic products, ...

FDA data breach startles drugmakers concerned about sensitive data

Damian Garde Hackers have found their way into the FDA's data vaults on investigational drugs, and industry groups are urging the agency to undergo a third-party audit to make sure ...

Drugmakers and legislators want an outside audit of the FDA’s hacking incident

Eric Palmer Hackers got into FDA computer systems recently, prompting the agency to warn drugmakers to be on the lookout for misuse of their credit and to change their passwords. But ...

OncoNova Discontinues Phase III Pancreatic Cancer Trial

barbara.lempert Onconova Announces Results of Interim Analysis of Metastatic Pancreatic Cancer Study NEWTOWN, Pa., Dec. 17, 2013 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. ...

GlaxoSmithKline bags FDA approval for blockbuster COPD contender

Damian Garde GlaxoSmithKline and Theravance scored another victory through their profitable partnership, winning FDA approval for Anoro Ellipta, a trailblazing COPD combo therapy with ...

As Pfizer Readies New Business Units, Amy Schulman Exits

esilverman Just a few months after Pfizer tapped general counsel Amy Schulman to head one of three so-called innovative business units that are supposed to take shape in January ...

Onconova tanks as its lead candidate flunks PhIII for pancreatic cancer

Damian Garde Onconova Therapeutics' shares took a 16% beating Tuesday night after the company's top prospect, rigosertib, failed a Phase III trial in patients with pancreatic ...

AstraZeneca’s Nexium gets a Korean competitor to chase it over the patent cliff

Carly Helfand The difference between magnesium salt and strontium salt may be enough to threaten U.S. sales of AstraZeneca's blockbuster Nexium–starting now. Reports say South ...

Chinese whistleblower tags Shanghai Pharma with bribery allegations

Tracy Staton Shanghai Pharma, one of China's largest drugmakers, said it is investigating whistleblower claims that it bribed hospital staffers to amp up sales of its drugs. According ...

Painful Erections: Another Reason To Worry About ADHD Pills

esilverman For parents who worry those ADHD pills may not be appropriate, here is another reason for concern – the FDA has just issued a notice saying methylphenidate products, ...
Page 4 of 6« First...23456
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS